Bridgeway Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Bridgeway Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-43,600	Closed	-$125K	–	1319
2024 Q3	$125K	Sell	43,600 -100,000	-70%	-$310K	﹤0.01%	1132
2024 Q2	$419K	Hold	143,600	–	–	0.01%	898
2024 Q1	$458K	Sell	143,600 -60,600	-30%	-$202K	0.01%	949
2023 Q4	$686K	Buy	204,200 +12,400	+6%	+$31.9K	0.01%	861
2023 Q3	$456K	Buy	+191,800	New	+$402K	0.01%	906

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Bridgeway Capital Management's PSTX Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 43,600 shares — an estimated $125K sold.

Bridgeway Capital Management first reported a position in PSTX in Q3 2023 and held it in 5 quarters. The position peaked at $686K in Q4 2023. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Bridgeway Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 43,600 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $125K.
Bridgeway Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2023 and held it in 5 quarters.
Bridgeway Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $686K in Q4 2023.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.